Revance Therapeutics (RVNC) Reports Publication of Pooled Results from Phase 3 Trials for Glabellar Lines

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/10/2026

1. META
2. SPY
3. USO
4. MSFT
5. COST
6. MU
7. IONS
8. ORCL
9. RMR
10. LEVI

Go back to Revance Therapeutics (RVNC) Reports Publication of Pooled Results from Phase 3 Trials for Glabellar Lines

Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology

December 5, 2019 8:00 AM EST

DaxibotulinumtoxinA for Injection (DAXI) demonstrated prolonged duration of response for glabellar line reduction

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today... More